RNase L activators and antisense oligonucleotides effective to treat RSV infections

{
  "publication_number": "US6214805B1",
  "country": "US",
  "kind": "B1",
  "title": "RNase L activators and antisense oligonucleotides effective to treat RSV infections",
  "abstract": "The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an \"antisense oligonucleotide\") coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.",
  "claims": [
    "1. A composition comprising: a) an oligonucleotide, comprising at least one 2′O methyl nucleotide, in which the oligonucleotide is complementary to between 15 and 20 nucleotides of a conserved gene-start or gene-end-signal of a genomic RNA strand of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; and b) an activator of RNase L attached to the linker.",
    "2. The composition of claim 1 in which the activator is selected from the group consisting of sp5′A2′(p5′A2′) 2 - O -, sp5′A2′(p5′A2′) 3 - O -, p5′A2′(p5′A2′) 2 - O -, and p5′A2′(p5′A2′) 3 - O -.",
    "3. The composition of claim 1 in which the oligonucleotide is blocked by a blocker selected from the group consisting of a -p3′N5′ nucleotide, a p-O-alkylamine, a p-O-hydroxyalkylamine, a sp-O-alkylamine, a sp-O-hydroxyalkylamine, ethyl and methyl.",
    "4. The composition of claim 1 in which the Respiratory Syncytial Virus is the A2 strain, and the portion of the genome is found in conserved regions of gene-start or gene-end signals.",
    "5. The composition of claim 1, in which the oligonucleotide contains one or more phospho-moieties selected from the group consisting of phosphorothioate, methylphosphonate and methylphosphonothioate.",
    "6. The composition of claim 1, in which the oligonucleotide is composed entirely of 2′ O-methyl nucleotides.",
    "7. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence: 3′ CCCCGUUUA 5′.",
    "8. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence: 3′ CCCUGUUUUA 5′ (SEQ ID NO:20).",
    "9. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence: 3′ UCAAUUNAUAUAUUUU 5′ (SEQ ID NO:21).",
    "10. A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of providing an amount of a complex effective to inhibit RSV infection, said complex comprising: a) an antisense oligonucleotide, in which the sequence of said oligonucleotide is complementary to between 15 and 20 nucleotides of a conserved region of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; and b) an activator of RNase L attached to the linker.",
    "11. A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of providing an amount of a complex effective to inhibit RSV infection, said complex comprising: a) an antisense oligonucleotide, having a hydroxyl moiety at a first end, in which the sequence of said oligonucleotide is complementary to between about 15 and 20 nucleotides of a normally single stranded portion of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; b) an activator of RNase L attached to the linker; and c) a pharmaceutically acceptable, aerosolizable carrier.",
    "12. The method of claim 10 or 11 in which the antisense oligonucleotide is 17 5′-3′-linked nucleotides.",
    "13. A composition to inhibit RSV infection in a mammalian cell comprising: a) an effective concentration of an oligonucleotide, wherein the oligonucleotide comprising at least one 2′ O-methyl modified nucleotide, is between 15 and 20 nucleotides of complementary sequence to a conserved gene-start or gene-end signal of a Respiratory Syncytial Virus genomic RNA strand and is attached to a RNase L activator by a linker; and b) a pharmaceutically acceptable carrier.",
    "14. The composition of claim 13, which comprises a pharmaceutically acceptable, aerosolizable carrier.",
    "15. The composition of claim 13 which is in a formulation suitable for nasal administration."
  ],
  "description_excerpt": "This application is a continuation-in-part of U.S. application Ser. No. 08/801,898, filed Feb. 14, 1997, now U.S. Pat. No. 5,998,602, which claims benefit of U.S. provisional application Serial No. 60/011,725, filed Feb. 15, 1996, each of which is incorporated herein by reference in its entirety.\n\nThe present invention relates to a chimeric molecule comprising an oligonucleotide complementary to a region of the genome of a negative strand RNA virus attached to an activator of RNase L (“activator-antisense complexes”) to specifically cleave a genomic strand, antigenomic strand or mRNAs of the RNA virus. The present invention relates to compounds useful for treating humans infected by RNA viruses, such as Respiratory Syncytial Virus (RSV), and methods of their use. Particularly, the invention relates to a complex of an oligonucleotide that is complementary to some portion of the genomic strand, antigenomic strand or mRNAs of RSV and a covalently linked activator of RNase L (henceforth, “activator-antisense complexes”). More particularly, the invention relates to activator-antisense complexes, in which the oligonucleotide is selected to bind to regions of the RSV RNA genome that possess repeated or consensus sequences. The invention further relates to activator-antisense complexes, in which the oligonucleotide is selected to bind to a portion of the RNA genome that normally has no self-hybridizing secondary structure.",
  "cpc": [
    "C12N 15/1131",
    "A61K 38/00",
    "A61K 47/549",
    "A61P 31/14",
    "C07H 21/00",
    "C12N 2310/31",
    "C12N 2310/315",
    "C12N 2310/321",
    "C12N 2310/341"
  ],
  "ipc": [
    "A61K 31/711",
    "A61K 48/00",
    "A61K 9/12",
    "A61P 31/14",
    "C07H 21/00",
    "C12N 15/09",
    "C12N 15/113"
  ],
  "assignees": [
    "Cleveland Clinic Foundation",
    "US Department of Health and Human Services"
  ],
  "inventors": [
    "Paul F. Torrence",
    "Robert Hugh Silverman",
    "Nick Mario Cirino",
    "Guiying Li",
    "Wei Xiao",
    "Mark R. Player"
  ],
  "filing_date": "1997-11-03",
  "publication_date": "2001-04-10",
  "grant_date": "2001-04-10",
  "priority_date": "1996-02-15",
  "application_number": "US-96269097-A",
  "family_id": "25506228",
  "cited_by_count": 174,
  "citations": [
    "WO1994009129A2",
    "US5583032A",
    "US5532130A",
    "WO1995022553A1",
    "WO1997014792A2"
  ]
}